Parker-Hannifin Corp (PH) Stock News

Law firm Bragar Eagel & Squire is investigating Alphatec Holdings for potential federal securities law violations following the company's May 5, 2026 earnings miss. Alphatec reported lower-than-expected Q1 2026 revenue, reduced full-year EOS revenue guidance, and disclosed unfulfilled unit commitments due to installation timing challenges. The stock price declined following the announcement.

The Law Offices of Frank R. Cruz announced a securities fraud class action lawsuit against Phreesia Inc., alleging the company made false statements about its growth outlook and revenue projections between May 2025 and March 2026. The lawsuit claims Phreesia misrepresented the reliability of its pharmaceutical marketing commitments as a growth driver for its Network Solutions segment, putting its 2027 revenue targets at risk. Investors who suffered losses have until July 13, 2026 to participate as lead plaintiffs.

The DJS Law Group has filed a class action lawsuit against Phreesia, Inc. (NYSE: PHR) for securities law violations under the Securities Exchange Act of 1934. The lawsuit alleges that Phreesia made false and misleading statements regarding its pharmaceutical marketing commitments as a growth engine for its Network Solutions segment while knowing of industry uncertainty that would impact revenue guidance. The class period spans May 8, 2025 to March 30, 2026, with a deadline of July 13, 2026 for shareholders to join the case.

Glancy Prongay Wolke & Rotter LLP announced a class action lawsuit against Phreesia Inc. for alleged securities fraud. The company allegedly misrepresented its revenue growth outlook and minimized risks in its Network Solutions segment. On March 30, 2026, Phreesia announced significantly lowered fiscal 2027 revenue projections, causing its stock to plummet 26.6% to $8.38 per share. Investors who purchased shares between May 8, 2025 and March 30, 2026 can file a lead plaintiff motion by July 13, 2026.

Rosen Law Firm has filed securities class action lawsuits against Phreesia Inc., Zoetis Inc., and ChampionX Corporation on behalf of investors who purchased securities during specified periods. The lawsuits allege that defendants made false or misleading statements regarding business conditions, including slowing demand and reduced visibility in key revenue streams.

Q1 Revenue Up 44% YoY; Same-Store Sales Up 29%; Adjusted EBITDA Turns Positive as Company Advances National Expansion Strategy EDMONTON, AB , June 1, 2026 /CNW/ - Dr. Phone Fix Canada Corporation (TSXV: DPF) ("Dr. Phone Fix" or the "Company"), one of Canada's fastest-growing and award-winning consumer electronics repair and resale platforms, today reported financial results for the three months ended March 31, 2026, and provided an update on recent corporate developments. The Company operates a network of 44 corporately owned stores across five Canadian provinces. Financial Results Summary (CAD) (all dollar amounts in 000's) Three Months Ended Mar 31, 2026 Three Months Ended Mar 31, 2025 Variance (%) Revenue 3,162 2,196 +44 % Gross Profit 1,621 1,210 +34 % Gross Margin 51.3 % 55.1 % -3.8 pp Operating Expenses (SG&A) 2,476 1,754 +41 % Adjusted EBITDA(1) 88 (13) n/m Cash 291 1,558 -81 % (1) See Non-GAAP Financial Measure towards the end of this document. "Q1 reflected continued progress in the execution of our strategy with revenue increasing 44% year-over-year and comparable-store sales increasing 29%, even in what is typically our seasonally weakest quarter," said Piyush Sawhney, Founder and Chief Executive Officer of Dr. Phone Fix. "We also delivered positive Adjusted EBITDA, generated positive operating cash flow, and continued to improve execution across our national network while integrating recently acquired locations and advancing our OEM, insurance, supplier, repair and certified pre-owned device programs." Mr. Sawhney continued, "We have spent the past year building the foundation for a national, carrier-neutral device lifecycle platform. Today, we have 44 corporately owned locations across five provinces, a growing pipeline of acquisition and greenfield opportunities, and a strategy focused on disciplined expansion and stronger unit-level economics throug

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Phreesia, Inc. (PHR), where investors who purchased stock between May 8, 2025 and March 30, 2026 may be entitled to compensation. The lawsuit alleges Phreesia made false statements about slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. Additional class actions are mentioned for Veritone, Inc. (VERI) and Stellantis N.V. (STLA). The lead plaintiff deadline for the Phreesia case is July 13, 2026.

A class action lawsuit has been filed against Graphic Packaging Holding Company for allegedly making false and misleading statements regarding inventory management issues, reduced demand, increased costs, and unreliable financial guidance for FY 2025. Investors who purchased GPK securities between February 4, 2025 and February 2, 2026 can seek lead plaintiff status by July 6, 2026.

Phreesia Inc. faces a securities fraud class action lawsuit after the company announced significantly lowered revenue growth projections for fiscal 2027 on March 30, 2026, citing macroeconomic factors and weaker pharmaceutical marketing commitments. The stock fell 26.6% following the announcement. Shareholders who purchased stock between May 8, 2025 and March 30, 2026 have until July 13, 2026 to file a lead plaintiff motion.

Public Policy Holding Company, Inc. (PPHC) announced that CEO Stewart Hall and Chief Administrative Officer Matthew Mazzanti will participate in 1x1 investor meetings at Stifel's Ninth Annual Boston Cross Sector Conference on June 3, 2026. The company, a global strategic communications provider serving approximately 1,500 clients across major economic sectors, reported Q1 2026 revenue growth of 27.5% with 5.1% organic growth compared to Q1 2025.

A securities fraud class action lawsuit has been filed against Phreesia Inc. after the company announced significantly lowered revenue growth projections for fiscal 2027 on March 30, 2026, citing macroeconomic factors and weaker pharmaceutical marketing commitments. The stock fell 26.6% following the announcement. Investors who purchased shares between May 8, 2025 and March 30, 2026 have until July 13, 2026 to file a lead plaintiff motion.

The Schall Law Firm is seeking investors who purchased Phreesia, Inc. securities between May 8, 2025 and March 30, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its long-term growth outlook and fiscal year 2027 projections, particularly regarding pharmaceutical marketing commitments as a growth driver for its Network Solutions segment. Investors who suffered losses are encouraged to contact the firm before July 13, 2026.

Robbins LLP has filed a class action lawsuit against Phreesia, Inc. on behalf of investors who purchased stock between May 8, 2025 and March 30, 2026. The lawsuit alleges that Phreesia misled investors regarding the sustainability of growth in its Network Solutions business and fiscal 2027 revenue outlook. The company failed to disclose weakening pharmaceutical marketing commitments and reduced visibility into future spending. On March 30, 2026, Phreesia lowered its fiscal 2027 revenue guidance from $545-$559 million to $510-$520 million, causing the stock to plunge approximately 27% in a single day.

A securities fraud class action lawsuit has been filed against Phreesia Inc. after the company announced significantly lowered revenue growth projections for fiscal 2027 on March 30, 2026, citing macroeconomic factors and weaker pharmaceutical marketing commitments. The stock fell 26.6% to $8.38 per share following the announcement. Investors who purchased shares between May 8, 2025 and March 30, 2026 may seek lead plaintiff status by July 13, 2026.

A class action lawsuit has been filed against Phreesia Inc. on behalf of investors who purchased stock between May 8, 2025 and March 30, 2026. The lawsuit alleges that Phreesia misrepresented its revenue growth projections and minimized risks in its Network Solutions segment. On March 30, 2026, Phreesia announced significantly lowered fiscal 2027 revenue projections, causing the stock to fall 26.6% to $8.38 per share. Investors have until July 13, 2026 to file a lead plaintiff motion.

A class action lawsuit has been filed against Phreesia Inc. on behalf of shareholders who purchased stock between May 8, 2025 and March 30, 2026. The lawsuit alleges that Phreesia misrepresented its revenue growth projections and minimized risks in its Network Solutions segment. On March 30, 2026, Phreesia announced significantly lowered fiscal 2027 revenue projections, causing the stock to fall 26.6% to $8.38 per share. Investors have until July 13, 2026 to file a lead plaintiff motion.

LSL Pharma Group Reports Record Q1-2026 Revenues while positioning for improved profitability following Steri-Med Pharma production resumption. Launch of new eye-drop portfolio planned for the second quarter of 2026. Secured US-FDA certification of Steri-Med to manufacture ophthalmic ointment for the US market. BOUCHERVILLE, QC , May 25, 2026 /CNW/ - LSL PHARMA GROUP INC . (TSXV: LSL ) (the " Corporation " or " LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2026 ("Q1-26"). All amounts are presented in millions ("M") of Canadian dollars. Q1-26 Corporate and Financial Highlights Record quarterly consolidated revenues, including full quarter contribution from Laboratoire Du-Var ("Du-Var") and Juno OTC acquired on January 1 st , 2026 and to be presented as 3 rd business segment; Strong Eye-Care revenues show significant market share gains in Canada; Q1-26 profitability temporarily impacted by the three-month Steri-Med Pharma (Steri-Med) production pause, with full production activities having resumed in April 2026; Secured US-FDA certification of Steri-Med to manufacture ophthalmic ointment for the US market; Commissioning of new state-of-the-art sterile ointment manufacturing line on track for commercial production by Q1-27; Development of three (3) new ointment products initiated for regulatory filings during FY-27. Binding term sheet signed with Instapill Private Limited ("Instapill") for the Canadian rights to private label Loratadine 10 mg Orally Disintegrating Tablets (ODT), a bioequivalent product to Claritin® Rapid Dissolve TM ; Revolving credit facility increased from $7.5M to $11M; "During the first quarter of 2026, we saw the positive impact of the recent acquisitions of Juno OTC and Du-Var on our operating results and the diversification of our business platform. Whil

Rosen Law Firm has filed a class action lawsuit on behalf of Phreesia, Inc. (NYSE: PHR) investors who purchased stock between May 8, 2025 and March 30, 2026. The lawsuit alleges that Phreesia made false and misleading statements regarding slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment. Investors who purchased during this period may be entitled to compensation. The deadline to serve as lead plaintiff is July 13, 2026.

Glancy Prongay Wolke & Rotter LLP announced a securities fraud investigation into Phreesia Inc. following the company's announcement on March 30, 2026 of significantly lowered revenue growth projections for fiscal 2027. The announcement cited macroeconomic factors and weaker pharmaceutical marketing commitments. Phreesia's stock fell 26.6% to $8.38 per share on March 31, 2026, prompting the law firm to urge affected shareholders to contact them about potential recovery claims.

Phreesia Inc. is under investigation for potential federal securities law violations following a significant stock price decline. On March 30, 2026, the company announced lowered revenue growth projections for fiscal 2027 due to macroeconomic factors and weaker pharmaceutical marketing commitments. The stock fell 26.6% to $8.38 per share on March 31, 2026. Shareholders who lost money are urged to contact the law offices to potentially pursue claims.

Robbins LLP announced a class action lawsuit against Phreesia, Inc. for allegedly misleading investors about the sustainability of growth in its Network Solutions business and fiscal 2027 revenue outlook. The company failed to disclose weakening pharmaceutical marketing commitments and reduced visibility into future spending, leading to a significant revenue guidance reduction from $545-559 million to $510-520 million. Phreesia's stock declined approximately 27% following the announcement on March 30, 2026. The lead plaintiff deadline is July 13, 2026.

PHYND, a free game streaming platform, launched in beta on Samsung Gaming Hub in the United States, offering console-quality games without requiring a console, download, or subscription. The service features titles from publishers like Microids and Fishing Cactus, with Samsung Smart TV models from 2022 and newer eligible for access.

Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.

The Schall Law Firm is seeking investors who purchased Phreesia, Inc. securities between May 8, 2025 and March 30, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding its long-term growth outlook and fiscal year 2027 projections, particularly regarding pharmaceutical marketing commitments as a growth driver for its Network Solutions segment.

SAPHNELO (Anifrolumab), a first-in-class type I interferon receptor blockade monoclonal antibody for moderate-to-severe SLE, is projected to see strong market growth through 2034 across major markets. The drug generated approximately $483 million in the first nine months of 2025 and has been approved in over 70 countries. However, the FDA issued a Complete Response Letter in February 2026 for the subcutaneous formulation, which AstraZeneca is working to address.

A securities class action has been filed against Phreesia, Inc. for allegedly making false and misleading statements about slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. The company reduced its fiscal year 2027 revenue guidance on March 30, 2026, citing weakness in pharmaceutical marketing, resulting in a 26.56% stock price decline. The deadline to seek lead plaintiff status is July 13, 2026.

Pomerantz LLP announced investigations into potential securities fraud and unlawful business practices at Phreesia, Zillow Group, and Whirlpool Corporation. The investigation into Phreesia was triggered by the company's March 30, 2026 announcement of reduced fiscal 2027 revenue guidance due to weakness in pharmaceutical marketing and poor visibility in its Networking Solutions segment, resulting in a 26.56% stock price decline.